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Summary
Background Carriage rates of Staphylococcus aureus on affected skin in atopic dermatitis
(AD) are approximately 70%. Increasing disease severity during flares and overall
disease severity correlate with increased burden of S. aureus. Treatment in AD
therefore often targets S. aureus with topical and systemic antimicrobials.
Objectives To determine whether antimicrobial sensitivities and genetic determi-
nants of resistance differed in S. aureus isolates from the skin of children with AD
and healthy child nasal carriers.
Methods In this case–control study, we compared S. aureus isolates from children
with AD (n = 50) attending a hospital dermatology department against nasal car-
riage isolates from children without skin disease (n = 49) attending a hospital
emergency department for noninfective conditions. Using whole genome
sequencing we generated a phylogenetic framework for the isolates based on
variation in the core genome, then compared antimicrobial resistance phenotypes
and genotypes between disease groups.
Results Staphylococcus aureus from cases and controls had on average similar numbers of
phenotypic resistances per isolate. Case isolates differed in their resistance patterns,
with fusidic acid resistance (FusR) being significantly more frequent in AD
(P = 0009). The genetic basis of FusR also differentiated the populations, with chro-
mosomal mutations in fusA predominating in AD (P = 0049). Analysis revealed that
FusR evolved multiple times and via multiple mechanism in the population. Carriage
of plasmid-derived qac genes, which have been associated with reduced susceptibility
to antiseptics, was eight times more frequent in AD (P = 0016).
Conclusions The results suggest that strong selective pressure drives the emergence
and maintenance of specific resistances in AD.
What’s already known about this topic?
• Staphylococcus aureus frequently colonizes individuals with atopic dermatitis (AD), with
increasing disease severity correlating with greater bacterial load of the organism.
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2018) 179, pp951–958 951
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
• Antimicrobial therapies are routinely used in AD for management and prevention
of disease flares.
What does this study add?
• Staphylococcus aureus isolates from children with AD differ in their antimicrobial resis-
tance profiles from those in healthy, nonatopic nasally colonized children.
• Fusidic acid resistance is significantly more prevalent in cases of AD, and arises
through distinct genetic mechanisms when compared with healthy controls.
• Carriage of plasmid-derived genetic determinants associated with antiseptic resis-
tance also clearly differentiated S. aureus from cases of AD and controls.
Fundamental to the success of Staphylococcus aureus as a pathogen
has been is its ability to become resistant to almost every class
of antibiotic. The sequential introduction of antimicrobials has
directly influenced the emergence and spread of the major
drug-resistant lineages of this organism.1 Generally we con-
sider the problems posed by resistance in terms of at-risk pop-
ulations, for instance methicillin-resistant S. aureus (MRSA)
transmission and invasive infection in hospital inpatients.
There are specific patient groups who have increased propen-
sity for S. aureus carriage and, as a corollary, infection.2 Com-
pared with the general population these patients are at higher
risk of drug resistance from frequent antimicrobial usage to
manage their condition. Patients with inflammatory skin disor-
ders exemplify this.
Atopic dermatitis (AD) is the most common inflammatory
skin disease of childhood, affecting up to 25% of children in
the U.K.3 Individuals with AD are specifically prone to colo-
nization by S. aureus. Cumulative observational evidence has
shown that 70% of patients with AD carry the bacterium on
lesional skin.4 Clinically, there is an observable link between
increasing disease activity and S. aureus carriage. Disease sever-
ity correlates with bacterial load5 and the immune response
mounted against it.6 Consequently, antimicrobial interventions
form part of routine care in this patient group. There is no
uniformly accepted diagnostic definition of colonization vs.
infection in AD, and practices pertaining to use of these treat-
ments vary between dermatologists and in the community.
Presently, there is a paucity of high-quality study evidence
supporting beneficial outcomes with usage of antimicrobials
in the management of AD flares, which raises the issue of
whether they should in fact be used at all.7,8
We aimed to determine whether there were phenotypic and
genotypic differences in antimicrobial resistance patterns in
S. aureus from the skin of children with AD compared with
S. aureus asymptomatically nasally carried by children without
skin disease.
Patients and methods
Ethics
Approval for these studies was obtained from the research
ethics committees of Our Lady’s Children’s Hospital or Temple
Street Children’s University Hospital, in Dublin, Ireland. Stud-
ies were conducted in accordance with the Declaration of Hel-
sinki, and written informed parental consent was obtained.
Patients
Children aged 0–7 years meeting the U.K. diagnostic criteria for
AD9 with moderate-to-severe disease were recruited through the
dermatology clinic at Our Lady’s Children’s Hospital, between
September 2012 and September 2014. Nonatopic, age-matched
controls were recruited during attendance with a noninfectious
illness at the emergency department, Temple Street Children’s
Hospital, during July and August 2009 as part of a separate S. au-
reus nasal carriage study by an independent study team. Full eligi-
bility and exclusion criteria for both studies were exactly as
previously described.10 Cases were swabbed at a single inflamed
skin site, while controls were swabbed from a single nostril,
with S. aureus isolation proceeding as previously published. All
isolates were then subjected to the same analyses. Sample sizes
were determined on the basis of what was practical and not from
a formal sample-size requirement estimate for this study.
Whole genome sequencing
Bacterial DNA extraction was carried out as described previ-
ously.11 DNA libraries were prepared with a Nextera XT
Library Preparation Kit (Illumina, San Diego, CA, U.S.A.) and
quantified with an Agilent Bioanalyser (Agilent, Santa Clara,
CA, U.S.A.). Libraries were normalized, pooled and sequenced
as 250-bp paired-end reads with a MiSeq sequencer (Illu-
mina). The sequence data have been deposited in the Euro-
pean Nucleotide Archive under project accession PRJEB25052.
Bioinformatic analysis
Multilocus sequence types were determined from sequence
reads using SRST2.12 Single-nucleotide polymorphisms (SNPs)
were identified by mapping sequence reads to the S. aureus ref-
erence genome MSSA47613 using SMALT.14 A maximum like-
lihood phylogeny was constructed using core genome SNPs as
described.11 Isolate resistance profiles were predicted in silico
from sequence reads with SRST2 by comparison with previ-
ously compiled resistance determinant databases for 18
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antimicrobials.15,16 Core chromosomal SNPs conferring resis-
tance were identified by manual inspection of the mapping data.
Antimicrobial sensitivity testing
Antimicrobial sensitivity (AMS) testing was performed on the
VITEK 2 instrument (BioMerieux, Marcy-l’Etoile, France)
using AST-P634 cards following the manufacturer’s instruc-
tions. Susceptibilities to all major antibiotic classes were tested
using minimum inhibitory concentration values determined to
benzylpenicillin, oxacillin, erythromycin, clindamycin, tetracy-
cline, fusidic acid, gentamicin, ciprofloxacin, trimethoprim,
mupirocin, linezolid, daptomycin, teicoplanin, vancomycin,
chloramphenicol and rifampicin. Strains were categorized as
susceptible or resistant based on European Committee on
Antimicrobial Sensitivity Testing breakpoint cut-offs assigned
using published criteria.17
Statistical analysis
Statistical analysis was undertaken using algorithms within
Stata 14.2 (StataCorp, College Station, TX, U.S.A.). Compar-
isons of unpaired proportions were derived from a modified
v2-test using the method described by Newcombe and Alt-
man.18 To aid interpretation of the relevance, 95% confidence
intervals (CIs) for observed differences in cases compared with
controls are presented. The significance threshold for all analy-
ses was set at 005. Each of the comparisons was decided
beforehand; we did not statistically adjust for multiple com-
parisons. All testing was two-tailed.
Results
Genetic backgrounds of Staphylococcus aureus from
cases and controls
Ninety-nine S. aureus isolates, 50 from cases of AD and 49 from
nasal carriage controls, underwent AMS testing and whole gen-
ome sequencing. The participant demographics are summarized
in Table S1 (see Supporting Information). Genomic analysis
revealed a diverse collection, with 19 individual sequence types
(STs) from 10 clonal complexes (CCs) in cases, and 16 STs repre-
senting nine CCs in controls. Comparison of case and control iso-
lates demonstrated that they were comprised of several dominant
clones (Table 1). In cases, CC1 isolates were the single most
prevalent, accounting for 20% of samples, compared with 8% of
controls. Isolates belonging to CC30 and CC45 predominated in
controls, making up 33% and 22% of samples, respectively,
compared with 10% and 14%, respectively, in cases. Isolates
from CC7, CC9 and CC59 were identified only in cases, whereas
CC22 and CC25 isolates were present only within controls.
Distribution of antibiotic resistance phenotypes
From AMS testing, the average number of resistances per iso-
late between cases and controls did not differ significantly
between the groups, with 15 antibiotics per isolate in AD and
13 in controls. Penicillin resistance was the most common
among all isolates; 92% were resistant to this beta-lactam
antibiotic. Comparison demonstrated that penicillin resistance
was less frequent in cases than in controls, present in 86% of
AD and 98% of control isolates (95% CI for difference 22%
to 2%, P = 0029). Prevalence of MRSA was low generally, in
4% and 2% of cases and controls, respectively (95% CI for
difference 5% to 9%, P = 057).
Between cases and controls there was no detectable differ-
ence in resistance to either the macrolide antibiotic ery-
thromycin or the lincosamide clindamycin, exhibited by 12%
of AD isolates compared with 6% of controls (95% CI for dif-
ference 5% to 17%, P = 031). Tetracycline resistance was
less frequent in cases than in controls, but this was not statisti-
cally significant (4% vs. 10%; 95% CI for difference 4% to
16%, P = 023). A single case sample was resistant to both
ciprofloxacin and gentamicin, while a single control was
trimethoprim resistant. None of the isolates was resistant to
vancomycin, daptomycin, linezolid, chloramphenicol, rifampi-
cin or teicoplanin (Table S1; see Supporting Information).
Resistance to fusidic acid, which is widely used topically for
superficial skin infections and in AD with topical corticos-
teroids, clearly differentiated the populations, with 24% more
AD isolates than controls exhibiting resistance (95% CI for dif-
ference 6–41%, P = 0009). Resistance to mupirocin, used
topically and commonly for MRSA decolonization, was present
in single isolates from each group (95% CI for difference
6% to 6%, P = 099).
Genetic basis of antimicrobial resistance
Whole genome sequencing of the isolates allowed us to obtain
a high-resolution view of the population structure of S. aureus
Table 1 Comparison of the clonal backgrounds of strains colonizing
either cases of atopic dermatitis (AD) or nasal carriage (NC) controls.
Singleton isolates that do not fall within a defined clonal complex are
presented as per their multilocus sequence type
Clonal complex (CC) or sequence
type (ST) of colonizing strain
Cases of
AD, n (%)
NC controls,
n (%)
CC1 10 (20) 4 (8)
CC5 6 (12) 8 (16)
CC7 3 (6) 0
CC8 7 (14) 1 (2)
CC9 3 (6) 0
CC15 3 (6) 1 (2)
CC22 0 5 (10)
CC25 0 1 (2)
CC30 5 (10) 16 (33)
CC45 7 (14) 11 (22)
CC59 3 (6) 0
CC121 1 (2) 1 (2)
ST779 1 (2) 1 (2)
ST1290 1 (2) 0
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from cases and controls, to pinpoint the genetic basis of resis-
tance and reconstruct their evolutionary context.
In silico characterization of the isolates’ resistome revealed
resistance determinants for penicillin (blaZ), methicillin (mecA),
erythromycin (ermA, ermC), tetracycline (tetK, tetM), ciprofloxacin
(mutation of gyrA, S84L, and grlA, S80F), gentamicin (aacA-phD),
trimethoprim (dfrG) and mupirocin (mutation of ileS-1, V588F)
(Table S1; see Supporting Information). The resistance pheno-
type and genotype were concordant, with four exceptions, all of
which were associated with penicillin resistance, where blaZ was
detected but the isolates were sensitive to this beta-lactam
antibiotic. Closer examination of the sequence revealed that two
isolates contained frameshift mutations within blaZ and two con-
tained frameshifts in the regulatory gene blaR (which is responsi-
ble for expression of blaZ), both of which would ablate
expression of blaZ.
Additionally we identified genes for resistance to antibiotics
not commonly used for treatment in AD, or routinely incor-
porated in AMS testing. Streptomycin resistance markers (AAD9
or aadE) were found in 12% of cases of AD vs. 6% of controls.
The amikacin resistance gene aphA-3 was detected in 4% of
S. aureus from cases compared with 2% from controls.
However, overall there were no significant differences in these
genes between the groups.
Finally, we assessed the WGS data for determinants of resis-
tance to disinfectants. In 16% of the S. aureus isolates from
cases of AD we identified qac genes, compared with 2% from
controls (95% CI for difference 3–25%, P = 0016). These
have been associated with reduced susceptibility to antiseptics
such as chlorhexidine and benzalkonium chloride,19 which are
commonly used in dermatological practice.
Distribution of resistance genes
We examined the distribution of antibiotic resistance determi-
nants within the population framework generated from the
core-genome phylogenetic analysis (Fig. 1). The penicillin
resistance gene blaZ was present in 94% of the S. aureus from
cases and 98% from controls, reflecting the widespread distri-
bution of beta-lactamases in the S. aureus population generally.
Of three mecA-carrying isolates (two cases and one control),
two belonged to ST779 (one case and one control) and one
belonged to ST8. The ermA and ermC genes, which confer resis-
tance to both erythromycin and clindamycin, were found in
Fig 1. Resistome profile of atopic dermatitis (AD) case and control isolates. Maximum likelihood tree of 99 isolates (50 cases of AD, 49 nasal
carrier controls) built with core genome single nucleotide polymorphisms. The case status of each isolate is indicated by the coloured cell (red,
AD; blue, nasal carrier control). Coloured cells then indicate the presence of resistance determinants to the antimicrobial agents penicillin (blaZ),
erythromycin (ermA, ermC), tetracyclines (tetK, tetM), methicillin (mecA), fusidic acid (fusB and fusC, mutations in fusA), trimethoprim (dfrG),
ciprofloxacin (mutations in gyrA/grlA), aminoglycosides (gentamicin, aacA-aphD; streptomycin, AAD9, aadE, aphA-3) and antiseptics (qacA, qacC, qacG
and qacJ). Blank cells indicate that the gene or mutation is absent.
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both patient groups, with ermA being more frequent in AD
samples, as expected given its high level of carriage in CC9
isolates, a CC present only in cases.
Tetracycline resistance genes tetK and tetM were both pre-
sent in control isolates of multiple clonal backgrounds, while
tetK was sporadically present in CC8 case isolates. Both
mupirocin-resistant isolates had the same point mutation in
ileS-1, but from differing clonal backgrounds, demonstrating
that they arose independently. Finally, the qac genes are seen
scattered throughout the population in multiple genetic
backgrounds. Taken as a whole, the distribution of these
determinants varied across the population, and cases and
controls could not be segregated on the basis of their resis-
tome.
Genetic basis of fusidic acid resistance
Phenotypic analysis suggested that fusidic acid resistance
(FusR) was significantly associated with AD. Three genotypes
responsible for FusR were identified, including acquired genes
fusB and fusC and chromosomal mutations in the gene fusA.
Overall fusB was the least prevalent FusR determinant, found
in 4% of cases compared with 2% of controls (95% CI for dif-
ference 5% to 9%, P = 057). Carriage of fusC was detected
in 20% of cases compared with 10% of controls (95% CI for
difference 4% to 24%, P = 017), and predominantly in
CC1 isolates (Fig. 2). Similarly, the difference in the propor-
tion of fusC-positive CC1 isolates between cases and controls
was not significant (95% CI for difference 6% to 96%,
P = 012). Point mutations in fusA were fourfold higher in
cases than in controls (16% vs. 4%; 95% CI for difference
0–23%, P = 0049). In total 12 mutations responsible for resis-
tance were identified in 10 resistant isolates, with four AD iso-
lates having multiple mutations (Table 1). Mutations in codon
461 of fusA, responsible for an amino acid substitution leucine
to serine at this position, were the most frequent (n = 4).
The phenotypic resistance observed varied depending on the
genetic determinant the isolate possessed, with the highest level
of resistance associated with fusA mutations (Table 2). High-
level resistance (minimum inhibitory concentration
> 32 lg mL1) in fusA mutants was detected in five isolates
(four cases, one control). As shown in Figure 2, the same fusA
Fig 2. Distribution of fusidic acid resistance determinants within the population. Maximum likelihood core phylogeny of all cases of atopic
dermatitis (AD) and nasal carrier (NC) controls. The branch colouring corresponds to the clonal background of the isolates. Taxon labels are
coloured according to case status (AD case red, NC control blue). Fusidic acid sensitive isolates are labelled as coloured circles (AD case red, NC
control blue). Resistant isolates are labelled according to the genetic determinant. In isolates with multiple fusA mutations, a single mutation is
presented on the branch, corresponding to either a previously reported amino acid change conferring resistance, or the most common. Singleton
isolates fall out with a defined clonal complex and include ST779 and ST1290.
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mutations were distributed in multiple CCs, suggesting that they
evolved independently, for example the substitution L461S in
CC8 and CC30 samples. This indicates that the prevalence of
FusR was not driven by expansion of one successful clone, but
rather by development of resistance in multiple clones, on mul-
tiple occasions, suggesting that a strong selective pressure has
been exerted by fusidic acid on the population.
Discussion
The association between disease activity and S. aureus means
that antimicrobials are frequently used in patients with AD.
Increasingly it is becoming evident that there are specific lin-
eages seemingly adapted to colonizing and surviving on AD-
affected skin.20 This analysis has demonstrated differences in
genetic backgrounds of S. aureus colonizing patients with AD
compared with controls, and a marked difference in the preva-
lence of topical antimicrobial resistance determinants among
children with AD.
Antimicrobial resistance is a concern in AD, often with
specific emphasis being placed on MRSA.21–23 Our results
demonstrated that MRSA prevalence in cases and controls was
low, just 4% and 2%, respectively. This reflects the population
prevalence of MRSA in this geographical locality where previ-
ous screening found MRSA in 16% of children aged
< 18 years (Desiree Bennett, personal communication).
Intriguingly, penicillin resistance was more common in con-
trol isolates (98%, vs. 86% in cases). While this difference
appears statistically significant, we hypothesize that assessment
of a larger sample size would void this difference, as penicillin
sensitivity in S. aureus in Europe and North America reportedly
varies between 8% and 13%.24,25 Erythromycin resistance was
twice as common in cases than in controls, but numbers were
small and this difference might have been a chance finding. It
is worth noting that macrolides are the usual alternative to
first-line penicillin-based agents for penicillin-allergic individ-
uals with AD flare; it is possible that with a much larger study
this difference may have been significant.
The relevance of the significantly greater prevalence of the
qac genes in cases of AD is uncertain. However, given the
widespread use of antiseptics in dermatology, it may be func-
tionally important. The reasoning for our cautious interpreta-
tion of this finding is the lack of clear genotype–phenotype
correlation with regards to the carriage of qac genes, as well as
issues surrounding the lack of standardized testing methods
for antiseptic susceptibility.26 Nonetheless, the potential for
them to function in reducing susceptibility to antiseptic com-
pounds used in AD warrants investigation.
From our analysis of antibiotic resistances between cases and
controls, the strongest signal of antibiotic selection came from
fusidic acid. This is among the most common interventions in
AD, principally in the community in the U.K. and Ireland.
Resistance was 25 times more frequent in cases, and displayed
greater diversity in the genetic determinants responsible for it.
Rates of FusR in S. aureus vary depending upon country and the
patient population sampled. One European surveillance survey
showed FusR in 118% of isolates from the U.K., while in Ire-
land this rate was higher at 199%.27 This is in contrast with
the U.S.A., where fusidic acid is not routinely used, and sensi-
tivity rates of 996% are reported.28 Higher rates of resistance
have been shown specifically within dermatology patients,
believed to be directly influenced by usage of topical fusidic
acid preparations.29 Conversely, resistance to mupirocin,
another topical anti-staphylococcal, was low in both groups,
likely because of comparatively low usage in Ireland.
Mechanistically, fusidic acid inhibits bacterial protein syn-
thesis through binding to translation elongation factor G
(fusA), a GTPase catalysing the final stage of peptide elonga-
tion. Resistance arises either via acquisition of a plasmid-
derived determinant or through point mutations in fusA. Two
acquired genes (fusB or fusC) and six nonsynonymous substitu-
tions were identified in the isolates. Placing these in phyloge-
netic context, we estimate that FusR arose at least 18 times in
the observed population. The basis of FusR also significantly
differentiated the populations. Both plasmid-derived FusR
determinants were present twice as frequently in case isolates.
Notably, fusC was found in 20% of cases, of which 70% were
from CC1 isolates. This determinant has been reported in the
context of its distribution in successful FusR clones belonging
to CC1, both methicillin sensitive and resistant alike.30,31
While fusC prevalence seems clonally influenced, the fusA
mutations are indicative of prior exposure and adaptation to
fusidic acid therapy. Numerous fusA SNPs were identified
across the whole population (Fig. 2), demonstrating that this
was the consequence of repeated independent events. Several
case isolates had multiple mutations in fusA. Previously it has
been reported that secondary mutations in fusA provide a
potential mechanism to offset the fitness deficit incurred by
maintaining this amino acid change.32
Table 2 Fusidic acid resistance (FusR) determinants identified in case
and control isolates, and associated minimum inhibitory
concentrations (MICs)
FusR
determinant
Amino acid
substitution
Number of
isolates
(case status)
Fusidic
acid MIC
(mg mL1)
fusA A307S,a L461S 1 (AD) 4
fusA L461S 2 (AD) 4
fusA E444K 1 (NC) 4
fusA V90I, A655Tb 1 (AD) 16
fusA A376V, P40Q,
L461S
1 (AD) > 32
fusA L461K 3 (2 AD, 1 NC) > 32
fusA T34S,a D283N,a
H457Y, P635La
1 (AD) > 32
fusB n/a 3 (2 AD, 1 NC) 8–16
fusC n/a 15 (10 AD, 5 NC) 8–16
AD, case of atopic dermatitis; NC, nasal carriage control; n/a,
not applicable. aNonsynonymous mutation without previously
published reports of impact of mutation on resistance. bMutation
at this codon previously reported but with different amino acid
substitution.36
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These observations raise several important points for clinical
consideration. Firstly, do our prescribing practices at a popula-
tion level select for specific colonizing strains in AD? Strain
prevalence in AD is an emerging area of interest, and little is
presently understood about the genetic basis of the preferen-
tial success of certain lineages, but this study supports the
recent findings of strain preponderance.20 Secondly, does
patient behaviour in addition to prescribing practice con-
tribute to the accumulation of fusA mutations in cases? Anec-
dotally, patients often report using repeated short bursts of
fusidic acid preparations at home for disease flares. Several
studies have that suggested both intermittent and prolonged
usage of such therapies is very likely to contribute to the
development of resistance.30,33 The patients with AD in this
study were attending a tertiary clinic for the first time, and
will likely have received this antibiotic in the community.
One limitation of this study was the lack of detailed prescrib-
ing records for the participants. The results nonetheless highlight
the importance of antimicrobial stewardship in this specific dis-
ease context. Finally we have to consider whether the use of any
antibiotic is warranted in many cases of AD flare. Recent clinical
trial evidence has clearly demonstrated a lack of objective benefit
of antimicrobials over use of a moderate-potency topical steroid,
at least in mild disease exacerbation.34,35
Future studies are specifically needed to assess the impact of
antimicrobial usage on S. aureus populations in AD. Topical
antimicrobials, both antibiotics and antiseptics, are of particu-
lar interest. These studies must incorporate both community-
based patients and those under specialist dermatological care,
and correlate with prescribing data. Patients of different ages
must be assessed to allow examination of the selective impact
of prescribing in dermatological and wider clinical practice.
With increasing evidence of lack of benefit of these treat-
ments, and growing resistance, we must reassess and change
our clinical practice accordingly.
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